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Zusammenfassung
Hintergrund: Bei Patienten mit operablem Rektumkarzinom gilt als
Standardbehandlung nach wie vor die chirurgische Resektion. Für
Patienten in fortgeschrittenem Krankheitsstadium wird eine post-
operative Radio-Chemotherapie (RCT) empfohlen. Ziel der vorlie-
genden Arbeit ist es, die Effektivität und Toxizität bei präoperativer
Bestrahlung in Kombination mit 5-Fluorouracil (5-FU) bei lokal fort-
geschrittenem Rektumkarzinom zu untersuchen. Patienten und
Methoden: Im Zeitraum von Juni 1999 bis September 2001 wurden
50 Patienten (13 weiblich, 37 männlich) mit lokal fortgeschrittenem
Rektumkarzinom untersucht. Der Altersdurchschnitt betrug 65,1
(Bereich 46–79,5) Jahre, 32 Patienten hatten einen uT3-Tumor, 14
Patienten einen uT4- und die restlichen 4 Patienten einem uT2-
Tumor. In Bezug auf den Lymphknotenstatus lag bei 22 Patienten
ein N0-Stadium vor. 2 Patienten hatten Lebermetastasen. Die Strah-
lentherapie wurde konformal über eine 4-Felder-Box-Technik bis zu
einer Gesamtdosis von 45,0 Gy (25 Fraktionen mit 5 ×1,8 Gy pro
Woche) appliziert. An den Tagen 1–5 und 29–33 erhielten die Patien-
ten 5-FU-Chemotherapie (500 mg/m2 pro Tag als Dauerinfusion).
Ergebnisse: Bei 56% der Patienten (n = 28) wurde eine pathologi-
sche Remission um mindestens ein T-Stadium erreicht, mit besse-
rem Erfolg bei tiefsitzenden Tumoren (64,0% der Patienten in dieser
Gruppe). Eine komplette Remission trat bei 4 Patienten (8,0%) und
ein Progress bei 3 Patienten (6,0%) auf. Im Rahmen der Operation
wurde bei 43 Patienten eine R0-Resektion erreicht, bei 7 Patienten
eine R1-Resektion (mikroskopischer Tumorrest). Die Toxizität (com-
mon toxicity criteria) im Rahmen der RCT bestand aus Dysurie Grad
I-II bei 5 Patienten (10,0%), Diarrhoe Grad I-II bei 20 Patienten
(40.0%) und schwerer Diarrhoe nur bei 2 Patienten (4,0%). Haut-
reaktionen Grad I-II traten bei 22 Patienten (44,0%) auf, schwerere
Hautreaktionen nur bei einem Patienten. Die akute postoperative
Morbidität bestand aus Abszess- oder Fistelbildung bei 8 Patienten
(16,0%), Anastomoseninsuffizienz bei 7 Patienten (14,0%). Schluss-
folgerung: Als Ergebnis kann festgehalten werden, dass die präope-
rative RCT mit moderater Toxizität durchführbar ist und eine
Tumorverkleinerung bewirken kann. Die Ergebnisse dieser Arbeit
bestätigen die vorläufigen Daten anderer Arbeiten über das neoad-
juvante Behandlungskonzept.
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Summary
Background: The standard therapy for patients with clinically re-
sectable rectal cancer is generally considered to be surgery. If the
patient is diagnosed with advanced disease, postoperative radio-
chemotherapy (RCT) is usually recommended. In our study we
aimed to investigate and analyze the effectiveness and toxicity of
preoperative pelvic radiotherapy in combination with 5-fluorouracil
(5-FU) in locally advanced rectal cancer. Patients and Methods:
From June 1999 to September 2001 we evaluated 50 consecutive
patients [37 male and 13 female; average age 65.1 (range 46–79.5)
years] with locally advanced rectal carcinoma. 32 patients were
staged as uT3, 14 as uT4, and 4 as uT2. Regarding N-staging, 22 pa-
tients were diagnosed as uN0. 2 patients had distant metastases,
with liver metastases in both instances. Conformal irradiation was
performed with a box technique (4-field technique) with a dose of
45 Gy (5 × 1.8 Gy per week for a total of 25 sessions). From days 1–5
and 29–33, all patients received 5-FU (500 mg/m2 per day, as a con-
tinuous i.v. injection). Results: Remission was observed in 28 pa-
tients (56%), with down-staging of at least one T-stage. A better suc-
cess rate was achieved for patients with  deep-seated tumors (64%
of the patients in this group). Complete remission was observed in
4 patients (8.0%) and progression in 3 (6.0%). 15 patients had no de-
tectable change in tumor staging (30.0%). A surgical R0 resection
could be achieved in 43 patients, an R1 resection (minimal margin)
in 7. Side effects and toxicity (common toxicity criteria) of RCT in-
cluded grade I-II dysuria in 5 patients (10%), grade I-II diarrhea in 20
patients (40%), and severe diarrhea in 2 patients (4.0%). Grade I-II
skin reaction was noticed in 22 patients (44.0%), severe skin reac-
tion only in 1 patient. Regarding acute postoperative morbidity, ab-
scess and fistula formation was noted in 8 patients (16.0%), with
anastomosis leakage in 7 (14%). Conclusion: Preoperative radio-
therapy appears to be a feasible therapeutic approach with moder-
ate toxicity and the potential to induce down-staging. The data pre-
sented in this study confirm the preliminary reports on this neoad-
juvant treatment.
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Colorectal cancer is one of the leading cancer-related causes
of death. In Germany, the incidence of colorectal carcinoma
amounts to 55,000–60,000 cases per year, one third of which
are rectal cancers. The mainstay of therapy has over the past
100 years been surgical resection. However, for the majority
of rectal cancers treated conventionally by resection alone,
locoregional recurrences are the major mode of failure [1].
Over the past decades, significant progress has been made in
developing effective adjuvant regimens. During the last
decade, substantial advances have been made with respect to
treatment modalities and surgical management with a shift
from radical operations to innovative sphincter-preserving
techniques.
Postoperative combined-modality therapy has significant-
ly contributed to improving local control and survival of
patients. The local recurrence rate has been reduced dra-
matically with the use of radiotherapy, especially when
combined with chemotherapy. Preoperative therapy
(combined radio- and chemotherapy) has the potential
advantages of producing less acute toxicity and increas-
ing the possibility of sphincter preservation. Preoperative
radiotherapy is becoming the standard of care for re-
sectable, locally advanced adenocarcinoma of the rectum,
being no longer limited to selected specialized cancer cen-
ters [2]. New and improved radiation techniques with con-
formal radiation and modern chemotherapeutic regimens
may have the potential to further increase the therapeutic
benefit.
Various reports on adjuvant treatment of advanced locore-
gional rectal carcinoma have been published, evaluating var-
ious radiation doses and chemotherapy regimens [3–11]. The
irradiation regimen varies from 25 Gy fractionated in 5 ses-
sions (hypofractionated radiotherapy) [10, 11] to convention-
al treatment between 36 and 50.4 Gy [3–9]. Some reports
also combined preoperative with postoperative irradiation
[7], others evaluated a combination treatment with hyper-
thermia [9]. All protocols included chemotherapeutic regi-
mens, especially 5-fluorouracil (5-FU) and leucovorin. They
differ, however, regarding the application modes and
chemotherapy doses.
The pretreatment diagnosis is generally based on comput-
ed tomography (CT) [12], magnetic resonance imaging
(MRI) [13, 14] or ultrasound (US) [15]. The effectiveness
of MRI in comparison to CT has previously been demon-
strated [14]. 
The objective of our current study is to evaluate down-stag-
ing and morbidity in the preoperative treatment of locore-
gionally advanced, rectal cancer with combined radio- and
chemotherapy. In this nonrandomized retrospective study
the morbidity and feasibility of this application method was
analyzed. The study analysis was based on the ARO/AIO/
CAO trial [6]. 
Material and Methods
From June 1999 to September 2001 we evaluated 50 consecutive patients
(37 male, 13 female) with an average age of 65.1 (range 46–79.5) years. All
patients had been diagnosed with locally advanced rectal cancer. 32 patients
suffered from a uT3 tumor, 14 patients had a uT4 and 4 patients a uT2
stage. Regarding N-staging, 24 patients were diagnosed as uN0 (table 1).
Histological grading was rated G2 in 42 patients, G3 in 6 patients, and
high-grade dysplasia in 2 patients. Staging was based on computed tomog-
raphy (CT), magnetic resonance imaging (MRI) and endosonography
[12–15]. Biopsies were taken during coloscopic control.
In 25 patients (50.0%) the tumor was localized up to 5 cm from the anal
verge (deep-seated tumor); in the remainder it was located more than 
5 cm from the anal verge (high-seated tumor).
The patients were selected for preoperative irradiation based on staging
results. The inclusion criteria were locally advanced rectal cancer with tu-
mors that either penetrated the muscular layer of the bowel wall or the
entire bowel wall (modified Dukes stages B) or spread to the lymph nodes
in the same region (Dukes stages C).
Irradiation was applied using conformal irradiation with a  box technique
(4-field technique) up to a dose of 45 Gy (5 × 1.8 Gy per week for a total
number of 25 sessions). From days 1–5 and days 29–33, the patients re-
ceived 5-FU (500 mg/m2 per day, 24-hour continuous infusion as is custom-
ary in our institution). 5-FU is a known radiosensitizer for rectal cancers.
However, the dose to be applied varies among the different studies [3–6]. 
Based on published data [16], all patients underwent surgical intervention
6–8 weeks after radiochemotherapeutic treatment (RCT). 11 patients had
an abdominoperineal rectal extirpation. The remaining 39 patients under-
went deep anterior rectal resection with total mesorectal excision.
An updated clinical re-staging with CT or MRI was performed in 37 pa-
tients shortly after termination of therapy. The remaining 13 patients were
operated in other hospitals and were not re-evaluated with CT and/or
MRI. The following parameters were evaluated: (1) clinical remission
after treatment, based upon CT and or MRI results [12–15]; (2) patholog-
ical remission after treatment based upon histological results after
surgery; (3) complication rate caused by RCT; (4) postoperative morbidi-
ty. No evaluation of survival rate was done due to the short follow-up
time. Morbidity and side effects were evaluated according to common tox-
icity criteria (CTC [17, 18]).
Results
The clinical evaluation after RCT including CT and/or MRI
findings demonstrated the following: In 15 patients no change
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Table 1. Patient characteristics
Age, years     
Median 64.1     
Range 46–79.5  
Gender, f/m 13/37  
Stage      
Dukes B  26     
Dukes C 24  
Grading      
G1   2     
G2 42     
G3   6  
Tumor distance from anal verge      
≤5 cm 25    
>5 cm 25  
was observed (40.5%); this held particularly true for patients
with deep-seated tumors (table 1). Partial clinical remission
(at least one T-stage) was noticed in 45.9% of patients, with
better results for high-seated tumors (50% of patients, table
2). Complete clinical remission was observed in only 3 pa-
tients (8.1%). Clinical progression was encountered in 2 pa-
tients with high-seated tumors (5.4%).
Pathological remission as compared to preoperative clinical
staging was noticed in 28 patients (56.0%), with improvement
of at least one T-stage (64.0% of the patients in this group)
(table 3). A higher success rate was noticed in deep-seated tu-
mors. Complete remission was observed in 4 patients (8.0%),
while progress was demonstrated in 3 patients (6.0%); in 15
patients (30.0%) no change in tumor staging was observed.
Surgical intervention achieved an R0 resection in 42 patients
and an R1 resection in 8 patients (minimal margin).
The toxicity of RCT was also evaluated according to CTC [17,
18] (table 4). Grade I-II dysuria was seen in 5 patients (10.0%)
and grade I-II diarrhea in 20 patients (40.0%). Severe diar-
rhea was observed in only 2 patients (4.0%), while a grade I-II
skin reaction was noticed in 22 patients (44.0%). A severe
skin reaction was found in only 1 patient.
The assessment of acute postoperative morbidity showed
(table 5) abscess and fistula formation in 8 patients (16.0%); in
7 of these patients a leakage of the anastomosis site was noted
(14.0%). Other side effects were delayed wound healing
(6.0%), bleeding (3 patients), and cardiac complications (2 pa-
tients). Avulsion of the anal ampulla was seen in 1 patient,
probably because of concrescence. Organ insufficiency was
observed in 1 patient shortly after the surgical intervention.
Discussion
Although preoperative chemo-irradiation for locally advanced
and high-risk rectal cancer improves the local recurrence rate
[19–20], its adverse effects are not well defined. Differing re-
ports on treatment regimens are the main problem [3–11].
Previous reports have demonstrated that neoadjuvant therapy
is a well-tolerated treatment for adenocarcinoma of the rec-
tum and that it may produce substantial down-staging and a
highly curative resection rate. Nevertheless, the optimal tim-
ing of surgery after preoperative RCT in rectal cancer is un-
known [16]. The study published by François et al. [16] pro-
posed an interval between 6 and 8 weeks as opposed to a
shorter interval of 2 weeks.
Chemo-irradiation has the potential to achieve a high re-
sponse rate, even though the toxicity of this treatment can
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No  Partial Complete Progression 
change remission remission 
   
n % n % n % n %  
Tumor distance from anal verge
≤5 cm 6 30.0 10 50.0 2 10.0 2 10.0
>5 cm 9 52.9 7 41.2 1 5.9    
Overall 15 40.5 17 45.9 3 8.1 2 5.4  
Table 2. Clinical evaluation after RCT (based
on CT or MR imaging). Subdivision between
patients with tumor distance from anal verge
≤5 cm and those with tumor distance from anal
verge >5 cm.
No  Partial Complete Progression 
change remission remission 
   
n % n % n % n %  
Deep-seated tumor 7 28.0 12 48.0 3 12.0 3 12.0  
High-seated tumor 8 32.0 16 64.0 1 4.0    
Overall 15 30.0 28 56.0 4 8.0 3 6.0  
Table 3a. Pathological evaluation after RCT
and tumor resection in comparison with the
clinical pretreatment status
Partial remission in n %  
Tumor 16 32.0  
Lymph nodes   6 12.0  
Tumor and lymph nodes 6 12.0 
Overall 28 50.0
Table 3b. Patients with pathologically 
confirmed partial remission, classified in tumor
remission, lymph node remission, and 
remission in both
sometimes be high. Some multicenter trials [5–7, 19–23] have
aimed to  evaluate the feasibility, morbidity and survival rate
after preoperative RCT. A comparison of these trials is not
easily done, since various treatment modalities, such as differ-
ing radiation doses (e.g. 5 × 5 Gy in the Dutch and Swedish
trial, or 45–50.4 Gy in the CAO/ARO/AIO-94 trial) [6, 21, 22]
and different administration routes of chemotherapy, were ap-
plied. Most of the studies published so far used 5-FU and leu-
covorin as both radiosensitizers and chemotherapy; however,
the dosage applied and the administration routes differed. All
trials were able to demonstrate the safety and feasibility of
neoadjuvant RCT. Bosset et al. [23] could demonstrate a 5-
year disease-free survival in 92% of patients with T3M0 rectal
cancer, when preoperative RCT was performed. The advan-
tages of RCT as opposed to radiotherapy alone are already
well known and accepted [3–11]. The most frequently used ra-
diosensitizer is 5-FU. However, the dosage to be administrat-
ed and the duration of the application are still subject to dis-
pute. The applied doses vary between 225 and 1,000 mg/m2 [6,
23, 24]. Attempts to find other radiosensitizers [25] demon-
strated Tagefur to have advantages over 5-FU in the treat-
ment of rectal cancer. A recent report [26] suggested that the
combination of oxaliplatin and irinotecan may have the po-
tential to further increase the therapeutic benefit of rectal can-
cer. The basic issue of timing (pre- or postoperative) within a
multimodal regimen is currently under investigation. Howev-
er, several reports were not able to demonstrate significant
down-staging after preoperative treatment [11]; it needs to be
taken into consideration, though, that the treatment regimens
reported in these studies included irradiation regimens of 5 × 5
Gy and surgical intervention within 10 days after RCT. In
comparison, other reported treatment regimens applied
40–50.4 Gy and performed surgery 4–6 weeks after preopera-
tive treatment [3–10]. With modern radiation techniques, pre-
operative radiotherapy can be delivered without any substan-
tial increase in postoperative mortality or morbidity and with
a low rate of late toxicity, provided that the radiation tech-
nique is optimal. 
Our results correlated well with the above-mentioned litera-
ture in that they achieved clinical and pathological down-stag-
ing in 45.9 and 56.0% of cases, respectively. The complete re-
mission rate was low (8.1% clinical and 8.0% pathological) as
is to be expected for locally advanced tumor. The correlation
between clinical and pathological staging is also confirmed
and corresponds to the already known literature [12–15]. 
The most common form of acute toxicity encountered during
adjuvant pelvic irradiation is diarrhea (approximately 24% of
the patients). Skin reaction (perineal dermatitis) is also known
(approximately 30–40%) [27]. The postoperative morbidity,
such as anastomotic leak (14.0%) and abscess formation
(16.0%), was higher as compared to reports on postoperative
irradiation regimens [6]. Bleeding and delay of wound healing
were the same in our preoperative group in comparison to
postoperative irradiation reports [6]. 
Our nonrandomized retrospective study analyzed the morbid-
ity and feasibility of this application method. A long-term sur-
vival rate evaluation was not possible as yet, since follow-up
times were still short, with a mean of 7.6 (range 3–26) months.
In conclusion, preoperative radiotherapy is a feasible method
with moderate toxicity and a potential to induce down-staging.
Our data confirm the preliminary reports about this neoadju-
vant treatment.
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Organ tissue Grade 1 Grade 2 Grade 3 Grade 4
   
n % n % n % n %  
Skin 12 24 10 20   1 2    
Genitourinary   4   8   1   2 – – – –  
Lower gastrointestinal, 
including pelvis 12 24   8 16   2 4 – –  
Table 4. Acute radiation-induced toxicities
(following CTC scoring criteria)
Complication n %  
Anastomosis leak 7 14.0  
Abscess / fistula 8 16.0  
Delay in wound healing 3   6.0  
Bleeding 3   6.0  
Cardiac complications 2   4.0
Table 5. Peri- and postoperative complications
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